CF Community Archives - Page 14 of 16 - The Boomer Esiason Foundation

March 19, 2019

SOURCE - VERTEX OFFICIAL PRESS RELEASE November 5, 2014 Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation -U.S. submission includes request for Priority Review; Accelerated Assessment has...

Alcresta Announces Agreement with CFF Therapeutics to Develop Point-of-Care Nutritional Products

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE - Marketwatch.com PRESS RELEASE April 17, 2014, 7:31 a.m. EDT Alcresta Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Develop Point-of-Care Nutritional Products Agreement Highlights Importance of Medical Nutrition in Managing Cystic Fibrosis NEWTON, Mass., Apr 17, 2014 (BUSINESS WIRE) -- Alcresta®, a leading medical nutrition company developing innovative...

Attention CF Patients with Persistent MRSA Lung Infection

by BEF

CF Community, CF News, Research

March 19, 2019

Attention CF Patients With Persistent MRSA Lung Infection: A Phase 2 clinical trial to evaluate the safety and efficacy of an inhaled anti-MRSA antibiotic is enrolling now. MRSA + CF The prevalence of MRSA lung infection in cystic fibrosis (CF) patients has risen in the past decade, currently...

Hearing Loss From Popular Cystic Fibrosis Antibiotic Could Be Treated With Vitamin Supplements

by BEF

CF Community, CF News, Research

March 19, 2019

SOURCE: Bionews-Tx.com Gentamicin belongs to the amino glycoside class of antibiotics and is used to treat mostly gram negative bacterial infections, including severe ones like pyelonephritis, biliary sepsis, endocarditis, and cystic fibrosis among others. It is a bactericidal antibiotic that binds irreversibly to the 30s subunit...

Kamada Ltd. Launching New CF Clinical Trial this Summer

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE [Posted by Mike Nace on bionews-tx.com] Israel-based Kamada Ltd., a drug development company currently developing plasma-derived protein therapeutics that are chiefly targeting orphan diseases, indicated recently in a press release that their lead drug candidate Alpha-1 Antitrypsin (AAT), which is currently in trials for treatment of...

CFF Therapeutics Extends Drug Development Collaboration via CFF.org

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE: CFF.org Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation, announced it will extend funding for continued collaboration with Proteostasis Therapeutics, Inc., for the development of new therapies to treat the most common CF mutation, Delta F508. Proteostasis will continue to focus...

FDA Advisory Committee supports the use of Novartis inhalation powder, Tobramycin

by BEF

Boomer Esiason Foundation, CF Community, CF News, Research, Therapies

March 19, 2019

The FDA Advisory Committee voted 13 to 1 that research showed adequate evidence to support the use of tobramycin inhalation powder by cystic fibrosis patients whose lungs contain the bacteria Pseudomonas aeruginosa, the leading cause of lung function loss in patients with CF. Tobramycin inhalation...

Gene Network Restores Cystic Fibrosis Protein Function

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

Source: Science Daily (July 31, 2012) Cystic fibrosis is an inherited disease caused by mutations in a gene that adversely affect its protein product. In its correct form and cellular location, this protein, cystic fibrosis transmembrane conductance regulator (CFTR), functions as a channel for ions to...

Final Results from Phase 2 Combination Study of Kalydeco and VX-809 Show Significant Improvements

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

Source: Cystic Fibrosis Foundation A Phase 2 clinical trial of Kalydeco™ in combination with VX-809 showed significant improvements in lung function in people with the most common CF mutation, according to final results announced today by Vertex Pharmaceuticals Inc. Both Kalydeco and VX-809, a CF drug in...

New Website Offers Insight on Cystic Fibrosis Gene Mutations

by BEF

CF Community, CF News, Research

March 19, 2019

Source: Cystic Fibrosis Foundation A major international research effort has led to a new online resource — www.CFTR2.org — that provides information about specific cystic fibrosis gene mutations to people with CF and their families, researchers, health professionals and the general public. The project is a collaboration...

CF Community

Vertex Submits Application for Combination Drug for People with 2 Copies of F508del Mutation

Alcresta Announces Agreement with CFF Therapeutics to Develop Point-of-Care Nutritional Products

Attention CF Patients with Persistent MRSA Lung Infection

Hearing Loss From Popular Cystic Fibrosis Antibiotic Could Be Treated With Vitamin Supplements

Kamada Ltd. Launching New CF Clinical Trial this Summer

CFF Therapeutics Extends Drug Development Collaboration via CFF.org

FDA Advisory Committee supports the use of Novartis inhalation powder, Tobramycin

Gene Network Restores Cystic Fibrosis Protein Function

Final Results from Phase 2 Combination Study of Kalydeco and VX-809 Show Significant Improvements

New Website Offers Insight on Cystic Fibrosis Gene Mutations

Never miss an update. Subscribe to our emails!